"Chemokine CXCL13" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A CXC chemokine that is chemotactic for B-LYMPHOCYTES. It has specificity for CXCR5 RECEPTORS.
| Descriptor ID |
D054382
|
| MeSH Number(s) |
D12.644.276.374.200.120.650 D12.776.467.374.200.120.650 D23.125.300.120.650 D23.469.200.120.650 D23.529.374.200.120.650
|
| Concept/Terms |
Chemokine CXCL13- Chemokine CXCL13
- CXCL13, Chemokine
- SCYB13 Chemokine
- Chemokine, SCYB13
- Chemokine (C-X-C Motif) Ligand 13 (B-Cell Chemoattractant)
- CXCL13 Chemokine
- Chemokine, CXCL13
|
Below are MeSH descriptors whose meaning is more general than "Chemokine CXCL13".
Below are MeSH descriptors whose meaning is more specific than "Chemokine CXCL13".
This graph shows the total number of publications written about "Chemokine CXCL13" by people in this website by year, and whether "Chemokine CXCL13" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2009 | 1 | 1 | 2 |
| 2011 | 0 | 2 | 2 |
| 2013 | 2 | 0 | 2 |
| 2017 | 0 | 1 | 1 |
| 2018 | 0 | 1 | 1 |
| 2019 | 0 | 1 | 1 |
| 2020 | 0 | 2 | 2 |
| 2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Chemokine CXCL13" by people in Profiles.
-
The age of the bone marrow microenvironment influences B-cell acute lymphoblastic leukemia progression via CXCR5-CXCL13. Blood. 2021 11 11; 138(19):1870-1884.
-
Unique Sjögren's syndrome patient subsets defined by molecular features. Rheumatology (Oxford). 2020 04 01; 59(4):860-868.
-
Circulating Plasma Biomarkers of Progressive Interstitial Lung Disease. Am J Respir Crit Care Med. 2020 01 15; 201(2):250-253.
-
Group 3 innate lymphoid cells mediate early protective immunity against tuberculosis. Nature. 2019 06; 570(7762):528-532.
-
Clinical Efficacy and Safety of Baminercept, a Lymphotoxin ß Receptor Fusion Protein, in Primary Sjögren's Syndrome: Results From a Phase II Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Rheumatol. 2018 09; 70(9):1470-1480.
-
Pneumocystis-Driven Inducible Bronchus-Associated Lymphoid Tissue Formation Requires Th2 and Th17 Immunity. Cell Rep. 2017 03 28; 18(13):3078-3090.
-
Altered Expression of CXCL13 and CXCR5 in Intractable Temporal Lobe Epilepsy Patients and Pilocarpine-Induced Epileptic Rats. Neurochem Res. 2017 Feb; 42(2):526-540.
-
B cells produce CXCL13 in lymphoid neogenesis during chronic obstructive pulmonary disease. The new kid on the block? Am J Respir Crit Care Med. 2013 Jun 01; 187(11):1162-4.
-
Interleukin-17-dependent CXCL13 mediates mucosal vaccine-induced immunity against tuberculosis. Mucosal Immunol. 2013 Sep; 6(5):972-84.
-
IL-23 is required for long-term control of Mycobacterium tuberculosis and B cell follicle formation in the infected lung. J Immunol. 2011 Nov 15; 187(10):5402-7.